Memory loss erodes identity, independence, and quality of life, and for most people it remains beyond the reach of effective treatment. HBOT’s potential role in memory is one of the more actively researched areas in the therapy’s cognitive applications. The mechanism is biologically credible: memory formation depends on the hippocampus, which is particularly vulnerable to reduced blood flow, and HBOT demonstrably improves cerebral perfusion and supports neuroplasticity. What the evidence actually shows is worth examining carefully. It is one of several range of brain conditions addressed with HBOT currently being explored in clinical research.
Why Memory Is Especially Vulnerable to Vascular Compromise
The hippocampus, located in the temporal lobe, is the brain’s primary center for forming new episodic memories and for converting short-term experiences into long-term storage. It is also one of the brain regions most sensitive to reduced blood flow. Even mild, chronic cerebrovascular insufficiency, the gradual decline in blood flow associated with vascular aging, arterial stiffness, and small vessel disease, can impair hippocampal function before producing symptoms elsewhere.
HBOT improves cerebral perfusion through two mechanisms: acute increase in plasma-dissolved oxygen reaching ischemic tissue, and longer-term promotion of angiogenesis (new blood vessel growth) in areas of vascular insufficiency. Multiple imaging studies have documented increased hippocampal blood flow following HBOT courses. Whether this translates into functional memory improvement, and in whom, is what the research is trying to establish.
Age-Related Memory Decline
The 2020 randomized trial from the Efrati lab found that healthy adults over 64 who received 60 HBOT sessions showed significant improvements on memory-related cognitive tests including verbal memory and visual-spatial memory tasks, alongside increased cerebral blood flow on imaging. These improvements occurred in people with normal baseline aging-related changes, not dementia.
This is encouraging data, but from one research group. The field needs independent replication of these findings to determine how generalizable they are. The broader cognitive health context is covered in the cognitive health and HBOT article.
Alzheimer’s Disease
Alzheimer’s is the most feared cause of memory loss, and the research question of whether HBOT might have a role in its management generates significant interest. The disease involves amyloid plaque accumulation, tau tangles, neuroinflammation, and progressive neurodegeneration, alongside vascular dysfunction that many researchers believe contributes to disease progression.
Animal studies in Alzheimer’s mouse models have shown reduced amyloid burden and improved cognitive performance with HBOT. Human studies are very limited. A small Israeli case series reported cognitive improvements and imaging changes in early Alzheimer’s patients after HBOT, but controlled human trials are lacking.
The honest assessment: HBOT for Alzheimer’s is research-stage science, not clinical medicine. The dementia and HBOT article covers this carefully and is worth reading for families navigating these decisions.
Post-COVID Memory Problems
Long COVID has created a large population of previously healthy individuals with new-onset memory problems: difficulty forming new memories, word-finding difficulties, and impaired recall that weren’t present before their COVID-19 infection. Neuroimaging research has found evidence of cerebral hypoperfusion in many of these patients, providing a direct mechanistic link to HBOT’s most established effect.
The 2022 randomized controlled trial by Zilberman-Itskovich found significant improvements in cognitive function including memory measures in long COVID patients receiving HBOT versus sham. This is among the more methodologically sound evidence for HBOT’s effect on memory in a specific population.
TBI-Related Memory Loss
Traumatic brain injury frequently impairs memory, both through direct damage to hippocampal and surrounding structures and through diffuse white matter injury affecting the networks that support memory retrieval. HBOT research in TBI populations has shown improvements in cognitive function including memory in some studies, though the evidence is mixed. The brain injury and HBOT article covers this evidence. For veterans with blast TBI and memory problems, the veterans and HBOT article is also relevant.
Stroke-Related Memory Loss
Stroke commonly causes memory impairment through direct damage to hippocampal tissue or through disconnection of the memory networks. HBOT’s role in stroke recovery includes potential benefit for memory-related impairments. The stroke and HBOT article covers the evidence for post-stroke cognitive recovery.
Practical Considerations
For most memory loss applications, HBOT would be off-label and out of pocket. Protocols used in cognitive and memory research involve 40 to 60 sessions at 1.5 to 2.0 ATA. The financial commitment is significant. The cost guide and insurance guide are important reference points. The session guide prepares you for what treatment involves.
Addressing Reversible Causes of Memory Loss First
Before pursuing HBOT for memory loss, ruling out and addressing reversible causes is essential. Many conditions that impair memory are treatable through other means: hypothyroidism, B12 deficiency, sleep apnea, depression, medication side effects (especially polypharmacy in older adults), poorly controlled blood pressure and blood glucose, and alcohol use. If any of these are contributing to your memory complaints, addressing them first may resolve or substantially improve memory function without HBOT, and optimizing these factors will improve your response to HBOT if you pursue it.
A thorough evaluation by a geriatrician, neurologist, or primary care physician with interest in cognitive health should include blood work for reversible causes, medication review, sleep assessment, and possibly neuropsychological testing before any conversation about HBOT for memory loss.
The Role of Vascular Risk Factor Management
Vascular cognitive impairment, memory and thinking problems caused by small vessel disease in the brain, is one of the most common causes of cognitive decline in older adults and one where HBOT’s vascular mechanisms are most directly relevant. Managing the risk factors that drive small vessel disease, hypertension, diabetes, high cholesterol, smoking, and atrial fibrillation, is both the most evidence-based approach to preventing further vascular cognitive decline and potentially the most important thing you can do to make HBOT maximally effective if you pursue it. HBOT’s angiogenic effects on ischemic brain tissue are most meaningful when the factors causing ongoing vascular damage are also being controlled.
Cognitive Rehabilitation Alongside HBOT
Cognitive rehabilitation, structured training of specific cognitive skills including memory strategies, attention training, and executive function exercises, has evidence for improving functional performance in people with cognitive impairment from various causes. Combining cognitive rehabilitation with HBOT during a treatment course may be more effective than either alone: HBOT provides the neurobiological substrate (improved perfusion, neuroplasticity support) while cognitive rehabilitation provides the activity-dependent stimulation that shapes how the brain uses that substrate. Discussing cognitive rehabilitation as part of a comprehensive treatment plan with your neurologist or neuropsychologist is worth pursuing alongside any HBOT consideration.
Sleep Apnea: A Treatable Driver of Memory Loss
Obstructive sleep apnea (OSA) is one of the most underdiagnosed and treatable causes of memory problems and cognitive decline, and it’s highly prevalent in older adults and in certain populations (obesity, large neck circumference, male sex). Repeated overnight oxygen desaturations in OSA cause measurable hippocampal volume loss over time and produce the same kind of daytime cognitive symptoms (memory complaints, difficulty concentrating, brain fog) that HBOT research is targeting. A patient with undiagnosed OSA pursuing HBOT for memory complaints may be spending significant money addressing a symptom rather than its treatable cause.
A sleep study (polysomnography or home sleep test) to screen for OSA is a low-cost, high-yield step that should precede any HBOT consideration for memory loss in at-risk individuals. Effective OSA treatment with CPAP or an oral appliance often produces meaningful improvements in cognitive function and memory. Adding HBOT after OSA has been treated and controlled may produce additional benefit in appropriate cases, but addressing the OSA first is clearly the right sequence.
Caregiver Considerations in Memory Loss and HBOT
For patients with memory loss significant enough to affect daily function, pursuing HBOT may require caregiver support for transportation, appointment management, and tracking symptom changes. Caregivers should be involved in the informed consent process and in establishing baseline and follow-up outcome measures. A family member or caregiver’s external observation of changes in memory-related behavior (navigating familiar routes, managing appointments, maintaining conversations, recalling recent events) can provide valuable objective data that complements formal cognitive testing, since patients with memory impairment may not always be the most accurate reporters of their own cognitive status.
The caregiver burden of supporting a loved one through 40 to 60 HBOT sessions five days per week is also worth acknowledging. For caregivers already managing a demanding caregiving role, the additional logistics of a prolonged HBOT course need to be factored into the decision, alongside the realistic likelihood and magnitude of benefit for the patient.
Frequently Asked Questions
Can HBOT restore memories that have already been lost?
HBOT cannot restore memories that have already been lost due to neuronal death or structural brain damage. It may improve the function of remaining memory circuits through improved perfusion and neuroplasticity support, potentially improving ongoing memory formation and retrieval efficiency. But it does not regenerate lost memories.
How soon after memory problems start should HBOT be considered?
Earlier intervention is generally more promising than later, as it may address the underlying vascular and inflammatory factors before irreversible neuronal loss occurs. For age-related decline and mild cognitive impairment, earlier treatment offers more to work with than end-stage dementia, where the structural brain changes are extensive. That said, there is no defined “window” after which HBOT is pointless; individual response varies considerably.
Are there ways to tell whether HBOT is likely to help my memory problems?
Transcranial Doppler, perfusion MRI, or SPECT imaging can assess cerebral blood flow. Finding documented hypoperfusion in memory-related brain regions provides stronger rationale for HBOT than having memory problems without documented vascular cause. A consultation with a hyperbaric physician who can review your imaging and history is the appropriate starting point for this assessment.
Sources
- Hachmo Y, et al. “Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells.” Aging, 2020. PubMed: PMID 33206062
- Boussi-Gross R, et al. “Hyperbaric oxygen therapy can improve post concussion syndrome years after mild traumatic brain injury.” PLoS One, 2013. PubMed: PMID 24040197
- Mayo Clinic. “Hyperbaric oxygen therapy.” Mayo Clinic, 2024. Mayo Clinic: Hyperbaric Oxygen Therapy
- Alzheimer’s Association. “What Is Alzheimer’s Disease?” Alzheimer’s Association, 2024. Alzheimer’s Association
References
- Hadanny A, et al. “Cognitive enhancement of healthy older adults using hyperbaric oxygen: a randomized controlled trial.” Aging. 2020;12(13):13740-13761. DOI: 10.18632/aging.103571
- Chen J, et al. “Hyperbaric oxygen ameliorates cognitive impairment in patients with Alzheimer’s disease and amnestic mild cognitive impairment.” Alzheimers Dement (Translational). 2020;6(1):e12030. DOI: 10.1002/trc2.12030
- Shahid A, et al. “HBOT for neurocognitive deficits following TBI: systematic review and meta-analysis.” Annals of Medicine and Surgery. 2025. DOI: 10.1097/MS9.0000000000003902
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
